烟碱型乙酰胆碱受体激动剂治疗精神分裂症认知功能损害的Ⅲ期临床试验公布更新资料

发布时间：2018-02-01 03:55

  本文关键词： 认知功能损害 Ⅲ期临床试验 激动剂 安慰剂对照 试验点 皮层神经元 共主 神经认知 临床疗效 评分表 　出处：《国际药学研究杂志》2016年04期 　论文类型：期刊论文

【摘要】：正FORUM制药有限公司宣布更新其2次烟碱型乙酰胆碱受体激动剂encenicline治疗精神分裂症认知功能损害的Ⅲ期临床试验资料,证实安全性和耐受性较佳,但均未能达到共主终点认知功能损害和患者功能较安慰剂组明显改善,这是由于安慰剂组也有较高有效率的影响,故结果尚需进一步分析。encenicline的26周Ⅲ期临床试验,包括2个平行、随机、双盲、安慰剂对照的研究,在200个试验点中评价了1500名精神分裂
[Abstract]:FORUM Pharmaceutical Co., Ltd. announced the update of its two nicotinic acetylcholine receptor agonist encenicline in the treatment of schizophrenia cognitive impairment phase III clinical trial data. It was proved that the safety and tolerance were better, but both of them failed to reach the common end point cognitive impairment and the patients' function was significantly improved compared with the placebo group, which was due to the effect of higher efficiency in the placebo group. Therefore, further analysis of .encenicline 's 26-week phase 鈪，

本文编号：1480868